Formulation Development and In Vitro Evaluation of Smart Nanoparticles for Delivery of Insulin and Pramlintide

Introduction: Diabetes is inability to produce insulin (Type1) or inability of cells to respond to insulin (Type2). For both persistent glycemic control is a key goal. Current insulin replacement therapy, SC injection, is not able to achieve a tight control of blood glucose levels. A pancreas-like, glucose-responsive insulin delivery system which is able to secrete insulin in response to elevated blood glucose, would regulate glycemia desirably with minimal patient effort. Some of glucose responsive delivery platforms contain glucose sensor and pH-sensitive part. Glucose sensing causes changes in pH of system and subsequent changes in pH-sensitive part and drug release. Insulin is not the only hormone secreted by pancreas b-cells, amylin is another one, so it can be an adjacent therapy to insulin, mimicking normal physiological condition and diminishing insulin need. In this study insulin and pramlintide (Amylin analogue) and glucose sensor were loaded in a pH-sensitive polymer to release the active insides in response to elevated glucose levels.Materials & Methods: Nanoparticles were fabricated by multiple emulsification method. RP-HPLC was used as the analytical method for determination of loading capacity and release profile.Results: Aforementioned nanoparticles showed acceptable loading of drugs. Release studies showed that the system respond to elevated glucose levels efficiently.Conclusion: Above-mentioned system can diminish insulin need in diabetic patients owing to pramlintide presence, and may mimic physiological conditions of healthy people.